Dual specificity mitogen-activated protein kinase kinase 2 (MEK2) (MEK2)

Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2), commonly known as MEK2, is a vital enzyme in the RAS/RAF/MEK/ERK signaling pathway, which regulates essential cellular processes such as proliferation, differentiation, and survival [1, 3, 9]. As a dual-specificity kinase, MEK2 phosphorylates both threonine and tyrosine residues on its only known physiological substrates, ERK1 and ERK2 [1, 10]. Dysregulation of this pathway, often caused by upstream mutations in BRAF or RAS, is a hallmark of various malignancies, including melanoma, colorectal, and non-small cell lung cancers [2, 13]. Additionally, germline mutations in MAP2K2 are associated with cardiofaciocutaneous (CFC) syndrome, a rare developmental disorder [3, 16]. Therapeutic targeting of MEK2 involves allosteric inhibitors that bind to a unique site near the ATP-binding pocket, locking the enzyme in an inactive conformation and preventing downstream ERK activation [8, 12]. These inhibitors, such as trametinib and cobimetinib, are frequently used in combination with BRAF inhibitors to overcome resistance and improve clinical outcomes in BRAF-mutant cancers [12, 13]. Clinical use of these drugs requires monitoring for specific toxicities, including dermatologic rash, gastrointestinal distress, and ocular or cardiac complications [13].

Other names

MAP kinase kinase 2MKK2MAPKK2PRKMK2ERK activator kinase 2CFC4

Allosteric inhibition of MEK1/2 kinase activity, preventing the phosphorylation and activation of downstream ERK1/2.